[go: up one dir, main page]

AR076188A1 - Derivados de oxadiazol - Google Patents

Derivados de oxadiazol

Info

Publication number
AR076188A1
AR076188A1 ARP100101117A ARP100101117A AR076188A1 AR 076188 A1 AR076188 A1 AR 076188A1 AR P100101117 A ARP100101117 A AR P100101117A AR P100101117 A ARP100101117 A AR P100101117A AR 076188 A1 AR076188 A1 AR 076188A1
Authority
AR
Argentina
Prior art keywords
hal
denotes
coor3
ocf3
denote
Prior art date
Application number
ARP100101117A
Other languages
English (en)
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of AR076188A1 publication Critical patent/AR076188A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos son utiles, por ejemplos en el tratamiento de trastornos autoinmunes, como, por ejemplo, la esclerosis multiple Reivindicacion 1: Derivado de oxadiazol de formula (1) donde R1, R2 de manera independiente uno del otro denotan H, Hal, CF3, OCF3, CN, o NO2, OH, S es OR3 o COOR3, Q denota (CH2)mX(CH2)m*, X es -NA-; W denota CH, Ra es un grupo de formula (2) donde Rs denota Hal, A, OR3, N(R3)2, NO2, CN, COOR3, CF3, OCF3, CON(R3)2, NR3COA, NR3CON(R3)2, NR3SO2A, COR3, SO2N(R3)2, SOA o SO2A, y G1, G2 de manera independiente uno del otro denotan H, Hal, o CH3, con preferencias H; Rb es A, CF3, CH3, Hal, OCF3, CN, NO2, N(R3)2, CH2(NR3)2, A denota un alquilo lineal o ramificado C1-6 con preferencia C1-3 donde un átomo de H puede ser reemplazado por Hal, OH, COOR3, CN, N(R3)2 y donde un grupo CH2 puede estar reemplazado por O, -NR3-, -NR3CO-, -CO- o S y/o por grupos -CH=CH- o -C:::C-, R3 es H o A m* es 1, 2, 3, 4. 5, 6, 7 u 8, y m es 1, 2, 3, 4, 5, 6, 7 u 8 donde por lo menos uno de Ra y Rb denota CF3, y sus derivados, solvatos, tautomeros, sales y estereoisomeros farmacéuticamente aceptables, con inclusion de sus mezclas en todas las relaciones.
ARP100101117A 2009-04-03 2010-04-05 Derivados de oxadiazol AR076188A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09157301A EP2241558A1 (en) 2009-04-03 2009-04-03 Oxadiazole derivatives
US16977309P 2009-04-16 2009-04-16

Publications (1)

Publication Number Publication Date
AR076188A1 true AR076188A1 (es) 2011-05-26

Family

ID=40792794

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100101116A AR076187A1 (es) 2009-04-03 2010-04-05 Derivados de oxadiazol, proceso de preparacion de los mismos y composicion farmaceutica que los contienen
ARP100101117A AR076188A1 (es) 2009-04-03 2010-04-05 Derivados de oxadiazol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP100101116A AR076187A1 (es) 2009-04-03 2010-04-05 Derivados de oxadiazol, proceso de preparacion de los mismos y composicion farmaceutica que los contienen

Country Status (16)

Country Link
US (2) US8802704B2 (es)
EP (3) EP2241558A1 (es)
JP (2) JP5833538B2 (es)
KR (2) KR20110135987A (es)
CN (2) CN102803238B (es)
AR (2) AR076187A1 (es)
AU (2) AU2010233932B2 (es)
BR (2) BRPI1013422A2 (es)
CA (2) CA2755928C (es)
EA (2) EA201171210A1 (es)
ES (2) ES2639028T3 (es)
IL (2) IL215497B (es)
MX (2) MX2011010451A (es)
SG (2) SG174449A1 (es)
WO (2) WO2010112461A1 (es)
ZA (2) ZA201106855B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
TW201206429A (en) * 2010-07-08 2012-02-16 Merck Serono Sa Substituted oxadiazole derivatives
CA2814628C (en) * 2010-10-14 2015-06-16 Daiichi Sankyo Company, Limited Acylbenzene derivative
EP2805941B1 (en) 2012-01-18 2016-08-17 Daiichi Sankyo Company, Limited Substituted phenylazole derivative
ES2782509T3 (es) 2012-07-02 2020-09-15 Monsanto Technology Llc Procedimiento para la preparación de 1,2,4-oxadiazoles 3,5-disustituidos
EP2958913B1 (en) 2013-02-20 2018-10-03 LG Chem, Ltd. Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
CN103450171B (zh) * 2013-09-22 2015-07-08 苏州康乃德生物医药有限公司 一种免疫调节化合物、其用途和包含其的药物组合物
US9828351B2 (en) * 2014-06-26 2017-11-28 Monash University Enzyme interacting agents
CN108348527A (zh) * 2015-10-30 2018-07-31 Ptc医疗公司 用于治疗癫痫的方法
WO2018187479A1 (en) 2017-04-04 2018-10-11 Case Western Reserve University Method of modulating ribonucleotide reductase
US10676467B2 (en) 2017-06-30 2020-06-09 Washington University Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof
CN107827837B (zh) * 2017-11-21 2021-09-24 苏州朗科生物技术股份有限公司 鞘氨醇-1-磷酸受体调节剂化合物及其制备方法与应用
CN109956912B (zh) * 2017-12-26 2021-10-22 中国医学科学院药物研究所 含二苯基噁二唑的羧酸类化合物、其制备方法及医药用途
CN109761827A (zh) * 2019-02-18 2019-05-17 湖南科瑞生物制药股份有限公司 一种n-苄基乙醇胺的制备方法
CN110987847B (zh) * 2019-12-11 2021-02-19 苏州今蓝纳米科技有限公司 1,3,4-噁二唑衍生物在检测酸以及数据加密和储存中的应用
CN116041277B (zh) * 2023-01-18 2024-11-01 中国药科大学 苯基和联苯基取代的五元杂环类化合物及其制备方法、药物组合物和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062248A2 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
US7605171B2 (en) * 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
EP1893591A1 (en) * 2005-06-08 2008-03-05 Novartis AG POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
GB0511684D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
JP2009269819A (ja) * 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
JP2010504932A (ja) * 2006-09-29 2010-02-18 ノバルティス アーゲー 抗炎症および免疫抑制特性を有するオキサジアゾール誘導体
GB0625648D0 (en) * 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
JO2701B1 (en) * 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
EP2125797B1 (en) * 2007-03-16 2014-01-15 Actelion Pharmaceuticals Ltd. Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
EP2014653A1 (en) * 2007-06-15 2009-01-14 Bioprojet Novel dicarboxylic acid derivatives as S1P1 receptor agonists
WO2009043889A2 (en) * 2007-10-04 2009-04-09 Merck Serono S.A. Oxadiazole derivatives
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives

Also Published As

Publication number Publication date
US20120022109A1 (en) 2012-01-26
US8815919B2 (en) 2014-08-26
CN102459206A (zh) 2012-05-16
IL215498A0 (en) 2011-12-29
EP2414342A1 (en) 2012-02-08
BRPI1015048A2 (pt) 2019-09-24
CA2755928C (en) 2017-06-20
IL215497B (en) 2018-12-31
EP2414341A2 (en) 2012-02-08
IL215497A0 (en) 2011-12-29
WO2010112461A1 (en) 2010-10-07
ZA201106854B (en) 2012-11-28
SG174448A1 (en) 2011-10-28
JP2012522744A (ja) 2012-09-27
EA201171211A1 (ru) 2012-05-30
EP2414341B1 (en) 2017-09-13
MX2011010449A (es) 2011-11-18
EP2241558A1 (en) 2010-10-20
US20120035226A1 (en) 2012-02-09
CA2755918A1 (en) 2010-10-14
CA2755918C (en) 2018-02-20
AU2010230314B2 (en) 2016-07-21
JP5833537B2 (ja) 2015-12-16
IL215498A (en) 2017-11-30
JP2012522745A (ja) 2012-09-27
EA201171210A1 (ru) 2012-05-30
AU2010233932A1 (en) 2011-10-13
ES2652183T3 (es) 2018-01-31
US8802704B2 (en) 2014-08-12
AU2010233932B2 (en) 2016-10-13
JP5833538B2 (ja) 2015-12-16
EP2414342B1 (en) 2017-05-31
ES2639028T3 (es) 2017-10-25
SG174449A1 (en) 2011-10-28
CN102803238A (zh) 2012-11-28
AR076187A1 (es) 2011-05-26
CN102803238B (zh) 2015-09-30
WO2010115751A2 (en) 2010-10-14
BRPI1013422A2 (pt) 2016-04-05
EA020691B1 (ru) 2015-01-30
ZA201106855B (en) 2012-11-28
WO2010115751A3 (en) 2010-12-16
CA2755928A1 (en) 2010-10-07
AU2010230314A1 (en) 2011-10-13
MX2011010451A (es) 2011-11-18
KR20120002606A (ko) 2012-01-06
KR20110135987A (ko) 2011-12-20

Similar Documents

Publication Publication Date Title
AR076188A1 (es) Derivados de oxadiazol
AR068730A1 (es) Compuestos de diaril 1,2,4-oxadiazol,composiciones farmaceuticas que los contienen,proceso de preparacion y uso de los mismos como agentes inmunosupresores en el tratamiento de enfermedades autoinmunes y/o inflamatorias cronicas.
AR068731A1 (es) Compuestos de diaril 1,2,4-oxadiazol,composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes inmunosupresores en el tratamiento de enfermedades autoinmunes y/o inflamatorias cronicas.
AR067877A1 (es) Compuestos de pirimidina
CO6321244A2 (es) Pirrolopiridinas como inhibidores de cinasa
AR083635A1 (es) Compuestos y derivados sustituidos de isoxazolina que contienen azolin para combatir plagas animales
AR075321A1 (es) Compuestos de amidina sustituida para combatir plagas de animales
AR076006A1 (es) Compuestos heterociclicos inhibidores de autotaxina utiles para el tratamiento de tumores, proceso para prepararlos y medicamentos que los contienen.
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
PE20120657A1 (es) Compuesto para el tratamiento de trastornos metabolicos
PE20110906A1 (es) Compuestos de arilo con sustituyentes heterociclicos como inhibidores hif
PE20160844A1 (es) Compuestos triciclicos como agentes anticancerigenos
PE20130039A1 (es) Pirazoles fungicidas
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
ECSP088479A (es) Derivados de oxadiazol
PE20141120A1 (es) Compuestos heterociclicos
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
AR079224A1 (es) Compuestos insecticidas basados en derivados de isoxazolina
AR064355A1 (es) Herbicidas derivados de isoxazol
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
PE20091843A1 (es) Inhibidores de catepsina c
AR076984A1 (es) Derivados de pirazol oxadiazol
ES2529691T3 (es) Derivados de 3-amino-imidazo [1,2-A] piridina como inhibidores de SGLT
CO6501157A2 (es) Sales de adición de trometamina con derivados de ácido azabifenilaminobenzoico como inhibidores de dhodh

Legal Events

Date Code Title Description
FA Abandonment or withdrawal